-logo.jpg "Veru logo")
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Read More…
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Phone305-509-6897
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.86 million
Profitability
Miscellaneous
Employees171
Next Earnings Date12/12/2019 (Estimated)
OptionableOptionable
Veru (NASDAQ:VERU) Frequently Asked Questions
What is Veru's stock symbol?
Veru trades on the NASDAQ under the ticker symbol "VERU."
How were Veru's earnings last quarter?
Veru Inc (NASDAQ:VERU) posted its earnings results on Thursday, August, 8th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.00. The company earned $9.73 million during the quarter, compared to analysts' expectations of $8.11 million. Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%. View Veru's Earnings History.
When is Veru's next earnings date?
What guidance has Veru issued on next quarter's earnings?
Veru updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29-32 million, compared to the consensus revenue estimate of $30.36 million.
What price target have analysts set for VERU?
6 brokerages have issued 12-month price objectives for Veru's shares. Their predictions range from $4.50 to $12.00. On average, they expect Veru's stock price to reach $6.4167 in the next twelve months. This suggests a possible upside of 237.7% from the stock's current price. View Analyst Price Targets for Veru.
What is the consensus analysts' recommendation for Veru?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.
What are Wall Street analysts saying about Veru stock?
Here are some recent quotes from research analysts about Veru stock:
- 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (9/13/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $300M. This includes a discounted cash flow-based asset value of $310M for FC2 and TADFIN, excluding $10M debt and using a 15% discount rate, 0% terminal growth rate and 80% probability of success for TADFIN. Risks include, but are not limited to: (1) failure of FC2 or TADFIN to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of TADFIN to obtain regulatory approval; (3) failure of other pipeline candidates; and (4) potential dilution risk." (8/9/2019)
Has Veru been receiving favorable news coverage?
News coverage about VERU stock has been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veru earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Veru.
Are investors shorting Veru?
Veru saw a drop in short interest in August. As of August 31st, there was short interest totalling 16,300 shares, a drop of 36.6% from the July 31st total of 25,700 shares. Based on an average daily volume of 230,700 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold. View Veru's Current Options Chain.
Who are some of Veru's key competitors?
Some companies that are related to Veru include Urogen Pharma (URGN), Precision BioSciences (DTIL), Aptorum Group (APM), Syros Pharmaceuticals (SYRS), Evolus (EOLS), Solid Biosciences (SLDB), Stemline Therapeutics (STML), Dova Pharmaceuticals (DOVA), SI-Bone (SIBN), Supreme Cannabis (FIRE), OraSure Technologies (OSUR), Akorn (AKRX), Spire Healthcare Group (SPI), Progenics Pharmaceuticals (PGNX) and Sinovac Biotech (SVA).
What other stocks do shareholders of Veru own?
Who are Veru's key executives?
Veru's management team includes the folowing people:
- Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
- Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
- Mr. O. B. Parrish, Co-Founder & Director (Age 86)
- Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
- Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)
Who are Veru's major shareholders?
Veru's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.22%), Vanguard Group Inc. (2.18%), Renaissance Technologies LLC (0.42%), BlackRock Inc. (0.35%) and Wedge Capital Management L L P NC (0.29%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Institutional Ownership Trends for Veru.
Which major investors are selling Veru stock?
Which major investors are buying Veru stock?
VERU stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Renaissance Technologies LLC, BlackRock Inc. and Perceptive Advisors LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Insider Buying and Selling for Veru.
How do I buy shares of Veru?
Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Veru's stock price today?
One share of VERU stock can currently be purchased for approximately $1.90.
How big of a company is Veru?
Veru has a market capitalization of $123.58 million and generates $15.86 million in revenue each year. The company earns $-23,930,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Veru employs 171 workers across the globe.View Additional Information About Veru.
What is Veru's official website?
How can I contact Veru?
Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]
MarketBeat Community Rating for Veru (NASDAQ VERU)
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
